Chemoprevention of esophageal squamous cell carcinoma - Clinical trials;Chemoprewencja raka płaskonabłonkowego przełyku - Badania kliniczne

Polski Merkuriusz Lekarski

Volumn 25, Issue 147, 2008, Pages 280-283

  Szumiło, Justyna ^a,b,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Department of Clinical Pathomorphology ^*

^c Uniwersytet Medyczny   (Poland)

Author keywords

Chemoprevention; Clinical trial; Esophagus; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT;

CHINESE MEDICINE; CLASSIFICATION; DIETARY FIBER; ESOPHAGUS TUMOR; HUMAN; MEDICINAL PLANT; MEDITERRANEAN DIET; PHYTOTHERAPY; REVIEW; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CARCINOMA, SQUAMOUS CELL; DIET, MEDITERRANEAN; DIETARY FIBER; ESOPHAGEAL NEOPLASMS; HUMANS; MEDICINE, CHINESE TRADITIONAL; PHYTOTHERAPY; PLANTS, MEDICINAL;

EID: 54149092051     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Baer-Dubowska W.: Nieodżywcze składniki roślin w chemoprewencji nowotworów oraz chorób serca i układu krażenia. Farm. Pol., 2000, 56, 1064-1070.
2. Blot W.J., Li J.Y., Taylor P.R. i wsp.: Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J. Natl. Cancer Inst., 1993, 85, 1483-1491.
3. Bosetti C., Gallus S., Trichopoulou A. i wsp.: Influence of the Mediterranean diet on the risk of cancers of the upper aerodigestive tract. Cancer Epidemiol. Biomarkers Prev., 2003, 12, 1091-1094.
4. Bosetti C., La Vecchia C., Talamini R. i wsp.: Food groups and risk of squamous cell esophageal cancer in northern Italy. Int. J. Cancer, 2000, 87, 289-294.
5. Burdan F, Chałas A., Szumiło J.: Cyklooksygenaza i prostanoidy - znaczenie biologiczne. Postepy Hig. Med. Dośw. (online), 2006, 60, 129-141.
6. Burdan F, Korobowicz A.: Koksiby - wysoce selektywne inhibitory cyklooksygenazy-2. Cz. I. Aktywność kliniczna. Pol. Merkuriusz Lek., 2003, 14, 348-351.
7. Corley D.A., Kerlikowske K., Verma R. i wsp.: Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and metaanalysis. Gastroenterology, 2003, 124, 47-56.
8. Dawsey S.M., Wang G.Q., Taylor P.R. i wsp.: Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the Dysplasia Trial in Linxian, China. Cancer Epidemiol. Biomarkers Prev., 1994, 3, 167-172.
9. Dabrowski A., Abramowicz K., Zinkiewicz K.: Epidemiologia raka przełyku. Pol. Merkuriusz Lek., 1998, 5, 84-86.
10. De Stefani E., Brennan P., Boffetta P. i wsp.: Vegetables, fruits, related dietary antioxidants, and risk of squamous cell carcinoma of the esophagus: a case-control study in Uruguay. Nutr. Cancer, 2000, 38, 23-29.
11. Ding P.L., Huang H., Zhou P. i wsp.: Quinolizidine alkaloids with anti-HBV activity from Sophora tonkinensis. Planta Med., 2006, 72, 854-856.
12. Ding Z., Gao R, Lin P.: Long-term effect of treating patients with precancerous lesions of the esophagus. Zhonghua Zhong Liu Za Zhi, 1999, 21, 275-277.
13. Engel L.S., Chow W.H., Vaughan T.L. i wsp.: Population attributable risks of esophageal and gastric cancers. J. Natl. Cancer Inst., 2003, 95, 1404-1413.
14. Gao Y.T., McLaughlin J.K., Blot W.J. i wsp.: Reduced risk of esophageal cancer associated with green tea consumption. J. Natl. Cancer Inst., 1994, 86, 855-858.
15. Gil J., Wojtuń S., Kozłowski W. i wsp.: Możliwości endoskopii w rozpoznawaniu i leczeniu nowotworów przełyku. Pol. Merkuriusz Lek., 2007, 22, 327-331.
16. Hou J., Lin P.Z., Chen Z.F. i wsp.: Field population-based blocking treatment of esophageal epithelia dysplasia. World J. Gastroenterol., 2002, 8, 418-422.
17. Jemal A., Siegel R., Ward E. i wsp.: Cancer statistics. 2007. CA Cancer J. Clin., 2007, 57, 43-66.
18. Launoy G., Milan C., Day N.E. i wsp.: Diet and squamous-cell cancer of the oesophagus: a French multicentre case-control study. Int. J. Cancer, 1998, 76, 7-12.
19. Li J.Y., Taylor P.R., Li B. i wsp.: Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J. Natl. Cancer Inst, 1993, 85, 1492-1498.
20. Limburg P.J., Wei W., Ahnen D.J. i wsp.: Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology, 2005, 129, 863-873.
21. Lin P.: Medicamentous inhibitory therapy of precancemus lesions of the esophagus - 3- and 5-year inhibitory effect of antitumor B, retinamide and riboflavin. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 1990, 12, 235-245.
22. Lin P., Chen Z., Hou J. i wsp.: Chemoprevention of esophageal cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 1998, 20, 413-418.
23. Lin P., Zhang J., Rong Z. i wsp.: Studies on medicamentous inhibitory therapy for esophageal precancemus lesions - 3- and 5-year inhibitory effects of antitumor-B, retinamide and riboflavin. Proc. Chin. Acad. Med. Sci. Peking Union Med. Coll., 1990, 5, 121-129.
24. Liu R.H.: Potential synergy of phytochemicals in cancer prevention: mechanism of action. J. Nutr., 2004, 134, supl.12, 3479S-3485S.
25. Milner J.A.: Diet and cancer: facts and controversies. Nutr. Cancer, 2006, 56, 216-224.
26. Niles R.M.: Signaling pathways in retinoid chemoprevention and treatment of cancer. Mutat. Res., 2004, 555, 81-96.
27. Rigas B., Kashif K.: Cancer prevention: a new era beyond cyclooxygenase-2. J. Pharmacol. Exp. Ther., 2005, 314, 1-8.
28. Soler M., Bosetti C., Franceschi S. i wsp.: Fiber intake and risk of oral, pharyngeal and esophageal cancer. Int. J. Cancer, 2001, 91, 283-287.
29. Sporn M.B., Suh N.: Chemoprevention of cancer. Carcinogenesis, 2000, 21, 525-530.
30. Stoner G.D., Morse M.A., Kelloff G.J.: Perspectives in cancer chemoprevention. Environ. Health Perspect., 1997, 105, supl.4, 945-954.
31. Stoner G.D., Wang L.S., Chen T.: Chemoprevention of esophageal squamous cell carcinoma. Toxicol. Appl. Pharmacol., 2007, 224, 337-349.
32. Terry P., Lagergren J., Ye W. i wsp.: Antioxidants and cancers of the esophagus and gastric cardia. Int. J. Cancer, 2000, 87, 750-754.
33. Tew W.P., Kelsen D.P., Ilson D.H.: Targeted therapies for esophageal cancer. Oncologist, 2005, 10, 590-601.
34. Wang G.Q., Dawsey S.M., Li J.Y. i wsp.: Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the General Population Trial in Linxian, China. Cancer Epidemiol. Biomarkers Prev., 1994, 3, 161-166.
35. Wang J.: Collaborative group for phase III clinical trial of Zeng Sheng-ping: Results of phase III clinical trial of zeng sheng-ping in the treatment of patients with esophageal epithelial hyperplasia. Zhonghua Zhong Liu Za Zhi, 2000, 22, 510-512.
36. Wang L.D.: Effect of added dietary calcium on human esophageal precancemus lesion in the high risk area for esophageal cancer-a randomized double blind intervention trial. Zhonghua Zhong Liu Za Zhi, 1990, 12, 332-335.
37. Wang L.D., Qiu S.L., Yang G.R. i wsp.: A randomized double-blind intervention study on the effect of calcium supplementation on esophageal precancerus lesions in a high-risk population in China. Cancer Epidemiol. Biomarkers Prev., 1993, 2, 71-78.
38. Wang L.D., Zhou Q., Feng C.W. i wsp.: Intervention and follow-up on human esophageal precancerus lesions in Henan, northern China, a high-incidence area for esophageal cancer. Can To Kagaku Ryoho, 2002, 29, supl. 1, 159-172.
39. Whanger P.D.: Selenium and its relationship to cancer: an update. Br. J. Nutr., 2004, 91, 11-28.
40. Zhang Z., Wang Y., Yao R. i wsp.: Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor models. Oncogene, 2004, 23, 3841-3850.